TABLE 2.
Clinical characteristics of cHF patients at baseline (n = 119).
| Patients characteristics | |
| Clinical history; n(%) cHF etiology | |
| Ischemic | 43 (36.1) |
| Non-ischemic | 76 (63.9) |
| Hypertensive cardiomyopathy | 19 (15.9) |
| Dilated cardiomyopathy | 24 (20.1) |
| Hypertrophic cardiomyopathy | 12 (10) |
| Heart valve disease | 17 (14.2) |
| Other | 4 (3.3) |
| New York Heart Association cHF stage | |
| NYHA I | 0 (0) |
| NYHA II | 52 (43.7) |
| NYHA III | 66 (55.5) |
| NYHA IV | 1 (0.8) |
| Hospitalizations in the 6 months prior study initiation | 49 (41.1) |
| Re-events in the year prior study initiation | 9 (7.6) |
| Percutaneous coronary intervention | 4 (44.5) |
| Coronary artery bypass grafting | 2 (22.2) |
| Medical treatment | 3 (33.3) |
| Biochemistry; mean ± SD | |
| Hemoglobin, mg/dl | 129.8 ± 18.5 |
| Creatinine, mg/dl | 1.3 ± 0.54 |
| C-Reactive Protein, mg/ml | 7.63 ± 11 |
| NT-proBNP, pg/ml | 2954.8 ± 4211.3 |
| High-sensitive troponin T, ng/l | 27.7 ± 20.9 |
| Erythrocytes, 106/mm3 | 3.98 ± 0.74 |
| Platelets, 103/mm3 | 173.2 ± 56.89 |
| Leukocytes, mm3 | 7426.1 ± 1950 |
| Neutrophils, 109/L | 4.74 ± 1.54 |
| Monocytes, 109/L | 0.75 ± 0.54 |
| Major outcomes during follow-up; n (%) | |
| Cardiovascular event † | 26 (21.8) |
| Stroke | 8 (6.7) |
| Aortic dissection | 1 (0.8) |
| AMI + Cardiogenic shock | 3 (2.5) |
| HTx/HTx waiting list | 10 (8.4)/1 (0.8) |
| CV death | 7 (5.8) |
| Emergency hospital admission for cHF | 16 (13.4) |
| Rehospitalisation for cHF | 57 (47.8) |
| Aortic aneurism | 1 (0.8) |
| Other death causes‡ | 10 (8.4) |
†Includes patients that suffered a stroke, an aortic dissection, an AMI, a cardiogenic shock, a CV death (mainly due to cHF) or were admitted to the emergency department. It does not include patients that underwent a HTx.
‡Includes patients that died due to a septic shock, a hemorrhage or a non-successful HTx. AMI, acute myocardial infarction; CV, cardiovascular; cHF, chronic heart failure; HTx, heart transplantation; NT-proBNP, N-terminal pro-hormone of brain natriuretic peptide; NYHA, New York Heart Association; SD, standard deviation.